All investors$550KQ1 2026Q1 2025
Agent Capital is a venture capital firm in Waltham, MA. It invests at seed to growth, it backs companies in Biotech and it leads or co-leads rounds.
Agent Capital
Waltham, MA
Healthcare VC investing in therapeutics for rare diseases, oncology, neurology and immunology, from seed to crossover rounds.Source
At a glance
- Stage
- Seed to Growth
- Industry
- Biotech
- Lead
- Leads or co-leads
- How to pitch
- Application form
What they look for
Agent Capital invests in therapeutics for rare diseases, oncology, neurology and immunology that address unmet patient needs. They participate across early and later stage financings, from preclinical through commercial development, and can lead or co-lead rounds alongside other investors.
Portfolio highlights
Affini-TAlveus TherapeuticsAshiBioCarbon BiosciencesCarisma TherapeuticsCerevanceCyrus BiotechnologyDice TherapeuticsDragonfly TherapeuticsEntrada TherapeuticsFlare TherapeuticsForesight DiagnosticsFreenomeGlycoEraHinge BioImCheck TherapeuticsImmunitas TherapeuticsInterius BioTherapeuticsMediar TherapeuticsMetagenomiNu-Tek BiosciencesOrbital TherapeuticsOrbus TherapeuticsOrchard Therapeutics
Latest fund
- Fund size
- $53M
Their largest fund closed in the last two years, per SEC filings. This is the fund's size, not a check size.
From SEC filings
Board seats1
Cantai Therapeutics, Inc.
Philadelpia, PA · Biotechnology
company round · Q3 2025
Companies where one of their partners holds a board or officer seat. Typical round: Under $1M. Amounts are the company's whole round, not this investor's check.
Named on filings1
Geeta Vemuri
Director and Executive Officer
Last filed 18 February 2026
Funds
Agent Capital Fund III LP
$53M closed of a $100M target
Agent Capital Fund III LP
$41M closed of a $100M target
3 venture funds in total. Shown here are the ones that filed in the last two years.
Fund filings by quarter
Q3 2024Q2 2026
SourcesLast updated 29 September 2026
Told us whether they lead, what they invest in, the stage they invest at and what they look for. Checked 23 September 2026.
Told us their logo and the one-line description above. Checked 23 September 2026.
Told us how they take pitches and how to apply. Checked 23 September 2026.
Told us their portfolio. Checked 23 September 2026.
Website
Confirmed as theirs on 22 September 2026.
SEC Form D, 2 filings
Funds, partners and board seats. Filed between 18 February 2025 and 18 February 2026.
SEC Form ADV
Firm name, office and fund count. CRD 288532. Last filed 6 April 2026.